# Claim Listing

### Claim 1 (canceled)

# 2. (previously presented) A pharmaceutical composition, wherein:

the composition comprises one or more orally deliverable dose units, each comprising a selective cyclooxygenase-2 inhibitory drug of low water solubility in a therapeutically effective amount, wherein the drug is present in solid particles having a weight average particle size of about 500 nm to about 900 nm;

the selective cyclooxygenase-2 inhibitory drug is a compound of formula:

R<sup>3</sup> is methyl or amino;

R<sup>4</sup> is hydrogen, C<sub>1-4</sub> alkyl, or C<sub>1-4</sub> alkoxy;

X is N or CR<sup>5</sup>;

R<sup>5</sup> is hydrogen or halogen; and

Y and Z are independently carbon or nitrogen atoms defining adjacent atoms of a five- to six-membered ring that is unsubstituted or substituted at one or more positions with oxo, halo, methyl, or halomethyl.

#### Claim 3 (canceled).

- 4. (previously presented) The composition of Claim 2 wherein the dose units are in the form of discrete solid articles.
- 5. (original) The composition of Claim 4 wherein the solid particles are tablets or capsules.

- 6. (previously presented) The composition of Claim 2 that is in the form of a substantially homogeneous flowable mass from which single dose units are measurably removable.
- 7. **(original)** The composition of Claim 6 wherein the substantially homogeneous flowable mass is a liquid suspension.

### Claims 8-11 (canceled)

- 12. (previously presented) The composition of Claim 2 wherein Y and Z are independently carbon or nitrogen atoms defining adjacent atoms of a ring selected from the group consisting of cyclopentenone, furanone, methylpyrazole, isoxazole, and pyridine rings substituted at no more than one position.
- 13. (previously presented) The composition of Claim 2 wherein the selective cyclooxygenase-2 inhibitory drug is selected from the group consisting of celecoxib, deracoxib, valdecoxib, rofecoxib, 5-chloro-3-(4-methylsulfonyl)phenyl-2-(2-methyl-5-pyridinyl)pyridine, 2-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-cyclopenten-l-one and (S)-6,8-dichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid.
- 14. (original) The composition of Claim 13 wherein the selective cyclooxygenase-2 inhibitory drug is celecoxib.
- 15. (original) The composition of Claim 14 comprising about 10 mg to about 1000 mg celecoxib in each dose unit.

#### Claims 16-18 (canceled)

19. (previously presented) A method of treating a medical condition or disorder in a subject where treatment with a cyclooxygenase-2 inhibitor is indicated, wherein:

the method comprises orally administering one or more dose units of a composition one to about six times a day;

the composition comprises a selective cyclooxygenase-2 inhibitory drug of low water solubility in a therapeutically effective amount, wherein the drug is present in solid particles having a weight average particle size of about 500 nm to about 900 nm;

the selective cyclooxygenase-2 inhibitory drug is a compound of formula:

$$R^{3}$$
  $R^{4}$ 

R<sup>3</sup> is methyl or amino;

R<sup>4</sup> is hydrogen, C<sub>1-4</sub> alkyl, or C<sub>1-4</sub> alkoxy;

X is N or CR<sup>5</sup>;

R<sup>5</sup> is hydrogen or halogen; and

Y and Z are independently carbon or nitrogen atoms defining adjacent atoms of a five- to six-membered ring that is unsubstituted or substituted at one or more positions with oxo, halo, methyl, or halomethyl.

- 20. (previously presented) The method of Claim 19 wherein the medical condition or disorder is accompanied by acute pain.
- 21. (previously presented) The method of Claim 19 wherein the dose units are in the form of discrete solid articles.
- 22. (previously presented) The method of Claim 21 wherein the solid articles are tablets or capsules.

- 23. (previously presented) The method of Claim 19 that is in the form of a substantially homogeneous flowable mass from which single dose units are measurably removable.
- 24. (previously presented) The method of Claim 19 wherein Y and Z are independently carbon or nitrogen atoms defining adjacent atoms of a ring selected from the group consisting of cyclopentenone, furanone, methylpyrazole, isoxazole, and pyridine rings substituted at no more than one position.
- 25. (previously presented) The method of Claim 19 wherein the selective cyclooxygenase-2 inhibitory drug is selected from the group consisting of celecoxib, deracoxib, valdecoxib, rofecoxib, 5-chloro-3-(4-methylsulfonyl)phenyl-2-(2-methyl-5-pyridinyl)pyridine, 2-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-cyclopenten-1-one and (S)-6,8-dichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid.
- 26. (previously presented) A method of making a medicament useful in treatment or prophylaxis of a COX-2 mediated condition or disorder, wherein:

the method comprises incorporation of a selective cyclooxygenase-2 inhibitory drug of low water solubility into a pharmaceutical composition comprising one or more orally deliverable dose units, wherein the drug is in the form of solid particles having a weight average particle size of about 500 nm to about 900 nm;

the selective cyclooxygenase-2 inhibitory drug is a compound of formula:

R<sup>3</sup> is methyl or amino;

 $R^4$  is hydrogen,  $C_{1-4}$  alkyl, or  $C_{1-4}$  alkoxy;

X is N or CR<sup>5</sup>;

R<sup>5</sup> is hydrogen or halogen; and

Y and Z are independently carbon or nitrogen atoms defining adjacent atoms of a five- to six-membered ring that is unsubstituted or substituted at one or more positions with oxo, halo, methyl, or halomethyl.

- 27. (previously presented) The method of Claim 26 wherein the dose units are in the form of discrete solid articles.
- 28. (previously presented) The method of Claim 27 wherein the solid articles are tablets or capsules
- 29. (previously presented) The method of Claim 25 that is in the form of a substantially homogeneous flowable mass from which single dose units are measurably removable.
- 30. (previously presented) The method of Claim 25 wherein Y and Z are independently carbon or nitrogen atoms defining adjacent atoms of a ring selected from the group consisting of cyclopentenone, furanone, methylpyrazole, isoxazole, and pyridine rings substituted at no more than one position.
- 31. (previously presented) The method of Claim 25 wherein the selective cyclooxygenase-2 inhibitory drug is selected from the group consisting of celecoxib, deracoxib, valdecoxib, rofecoxib, 5-chloro-3-(4-methylsulfonyl)phenyl-2-(2-methyl-5-pyridinyl)pyridine, 2-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-cyclopenten-1-one and (S)-6,8-dichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid.